paroxysmal atrial fibrillation
Conditions
Interventions
Intervention group:1 month postoperatively, class I or class III antiarrhythmic drugs were used, except for amiodarone
Control group:Routine use of class I or III antiarrhythmic drugs for 3 months after surgery, except amiodarone
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 years or older; 2.Patients diagnosed with paroxysmal atrial fibrillation and planning to undergo pulsed ablation; 3.Patients undergoing the first ablation treatment for atrial fibrillation this time; 4.Patients who can and are willing to wear an electrocardiogram monitoring device during the study and upload the data; 5.Patients who can and are willing to provide the specified observational data and/or participate in the baseline and follow-up assessments of the entire study.
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with persistent atrial fibrillation; 2. Patients with atrial fibrillation secondary to electrolyte imbalance, thyroid disease, alcohol or other reversible/non-cardiac causes; 3. Patients, according to the investigator's judgment, who have any known contraindications for pulse ablation system, anticoagulation therapy or contrast agent use and atrial fibrillation ablation; 4. Any patients who have known inability to obtain vascular access or have contraindications for femoral vein puncture; 5. Patients with any of the following atrial heart diseases: a. Left atrial (LA) anterior-posterior diameter >= 5.5 cm measured by transthoracic echocardiography (TTE) within 3 months before surgery; b. Any previous atrial endocardial, epicardial or surgical ablation surgery for arrhythmia, except for right tricuspid isthmus ablation or right supraventricular tachycardia; c. Current atrial myxoma or left atrial thrombus; d. Any pulmonary vein abnormality, stenosis or stent implantation (including common pulmonary veins and middle pulmonary veins); 6. Patients with cardiovascular events in the past 3 months (including acute myocardial infarction, coronary intervention, coronary artery bypass surgery, artificial valve replacement or repair, atrial or ventricular incision); 7. Patients with heart failure diagnosed by transthoracic echocardiography within 3 months before surgery with left ventricular ejection fraction < 40%; 8. Patients undergoing or expected to undergo implantation of pacemaker, implantable cardioverter-defibrillator and cardiac resynchronization therapy device and through atrial septal patch or barrier for atrial septal defect closure or patent foramen ovale closure; 9. Patients for whom I/III class anti-arrhythmic drugs cannot be discontinued due to non-atrial rhythm causes; 10. Patients according to the investigator's judgment, with an expected life expectancy of less than one year before surgery; 11. Pregnant patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Long-term success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment success rate;Atrial fibrillation burden;The proportion of participants with a fibrillation load greater than 0.1%;The incidence rate of major complications; | — |
Countries
China
Contacts
Public ContactRui Zeng
West China Hospital of Sichuan University
Outcome results
None listed